Single-agent therapy for acute pelvic inflammatory disease: Sulbactam/ampicillin versus cefoxitin

D. L. Hemsell, R. E. Bawdon, P. G. Hemsell, B. J. Nobles, M. C. Heard

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


A total of 54 women with acute salpingitis were treated intravenously with ampicillin/sulbactam or cefoxitin in a prospective, randomized, ongoing study. Of the organisms isolated, Gram-negative species (excluding Neisseria gonorrhoeae) were considerably more likely to produce β-lactamase than were Gram-positive species. Clinical efficacy was 94% for 2 g ampicillin plus 1 g sulbactam and 89% for 2 g cefoxitin, all given intravenously every 6 h. The addition of sulbactam, an irreversible β-lactamase inhibitor, to ampicillin restored both the microbiological and clinical activities of ampicillin. Both regimens were equally safe and demonstrated good efficacy in the treatment of the acute, symptomatic phase of infection.

Original languageEnglish (US)
Pages (from-to)85D-89D
JournalJournal of International Medical Research
Issue numberSUPPL. 4
StatePublished - Jan 1 1990


  • acute pelvic inflammatory disease
  • ampicillin
  • cefoxitin
  • salpingitis
  • sulbactam

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical


Dive into the research topics of 'Single-agent therapy for acute pelvic inflammatory disease: Sulbactam/ampicillin versus cefoxitin'. Together they form a unique fingerprint.

Cite this